A 2024 narrative review by Diotaiuti and colleagues synthesizes the current evidence on neurofeedback as a non-pharmacological tool for chronic pain management, bringing together findings from clinical trials, observational studies, and case reports. This is new emerging research with novel insights because it highlights not only whether neurofeedback can help, but also how different protocols may interact with different pain conditions—and why people respond so differently.

Chronic pain is commonly defined as pain that persists or recurs for more than three months, and it can become much more than a lingering symptom. Over time, pain can “teach” the nervous system to stay on high alert, affecting sleep, mood, attention, and daily functioning. This is why approaches that target the brain-body system—not just the site of pain—have become increasingly important.

Neurofeedback (often called EEG biofeedback) is a form of learning in which a person receives real-time information about their brain activity and practices nudging it in a healthier direction. Biofeedback more broadly refers to using real-time physiological signals (like breathing, heart rate, or muscle tension) to build self-regulation skills. In the context of chronic pain, these methods are compelling because pain is not only a sensory experience; it is also shaped by attention, emotion, stress physiology, and the brain’s capacity for neuroplastic change.

Think of chronic pain like a smoke alarm that keeps chirping long after the fire is out. Neurofeedback doesn’t “erase the alarm,” but it may help recalibrate the sensitivity of the system that keeps detecting threat—especially when that system has become overly vigilant.

Methods

This paper is a narrative review rather than a systematic review or meta-analysis. The authors chose this approach because the neurofeedback-for-pain literature is highly heterogeneous: studies vary in pain condition (e.g., fibromyalgia, tension-type headache, chronic low back pain, central neuropathic pain), neurofeedback modality (EEG, infra-low frequency approaches, volitional limbic neuromodulation, SMR-based training, alpha-wave training, and real-time fMRI neurofeedback), outcome measures, and study quality. Narrative synthesis allows the field to be summarized without forcing “apples-to-oranges” comparisons.

The authors report searching multiple databases and grey literature sources and then applying inclusion/exclusion criteria to focus on studies specifically addressing neurofeedback’s efficacy for chronic pain. The final selection included 17 studies spanning randomized controlled trials, observational designs, pilot studies, and systematic reviews/meta-analyses.

A major methodological theme throughout the review is protocol variability. EEG-based neurofeedback studies commonly focus on training oscillatory activity—such as alpha (8–12 Hz), theta (4–8 Hz), and SMR (typically 12–15 Hz)—based on the idea that these rhythms relate to arousal regulation, sensory gating, and pain modulation. The review also notes individualized approaches that aim to match training parameters to each person’s electrophysiology, acknowledging that the same pain diagnosis can involve different brain signatures.

Session “dose” varies substantially across the literature. Some work reports intensive schedules (e.g., 40+ sessions in some fibromyalgia protocols), whereas other studies used shorter courses (e.g., around 10 sessions for tension-type headache prevention). Session length also varies widely, from brief trainings under 10 minutes in some contexts to more typical sessions around 30–45 minutes, with multi-session packages commonly ranging from 20 to 40 sessions.

The review also discusses mechanistic framing: neurofeedback is conceptualized as operant conditioning of brain states, where repeated practice + feedback may shape neural networks implicated in pain perception and regulation.

Results

Across the included studies, neurofeedback is generally associated with improvements in pain-related outcomes—most notably reductions in pain intensity and improvements in quality of life, with some reports also noting reduced reliance on medication. However, the magnitude and reliability of effects vary by pain condition, protocol, and individual response.

The review highlights several clusters of findings:

• Fibromyalgia: Multiple studies suggest symptom improvement with EEG biofeedback and related approaches. Some trials report pain reduction and broader improvements in psychological symptoms and quality of life, while other work points to variability in outcomes, reinforcing the need for personalization.

• Headache disorders (including tension-type headache and migraine): Sham-controlled and QEEG-guided approaches show promise for reducing headache frequency, with the broader literature suggesting neurofeedback may function as both preventive and symptom-reducing support.

• Chronic low back pain: Alpha-wave neurofeedback, especially when integrated alongside conventional treatments, shows a clinically meaningful short-term effect on pain intensity in at least one intervention study.

• Central neuropathic pain after spinal cord injury and complex regional pain syndrome: EEG-based neurofeedback appears capable of producing both immediate and longer-term reductions in pain, sometimes accompanied by measurable changes in cortical activity or functional connectivity.

The review also flags adverse effects. While many studies report minimal or transient side effects, some note temporary symptom exacerbation (e.g., fatigue, pain flare), and the broader neurofeedback literature recognizes that side effects can occur, emphasizing careful monitoring and individualized adjustment.

Finally, the authors underscore the evidence-quality issue: while signals are encouraging (including a medium effect size reported in an external systematic review/meta-analysis they cite), the overall certainty remains limited due to small samples, heterogeneous methods, and a shortage of rigorous sham-controlled trials.

Discussion

Taken together, the review paints neurofeedback as a plausible, brain-based companion to multidisciplinary chronic pain care—especially for people who have not responded well to medication alone or who want options that reduce long-term pharmacological burden. The most clinically useful message is not that “neurofeedback cures pain,” but that it may help people regain influence over the nervous system patterns that keep pain loud.

One reason neurofeedback fits chronic pain so well is that pain has a strong central component. Chronic pain is associated with changes in networks involved in salience detection, sensory processing, emotion, and executive control. In practice, this often looks like a nervous system that struggles to downshift: sleep is lighter, attention is stickier around threat, and the body runs closer to the edge of its stress capacity. Neurofeedback aims to train steadier brain states, potentially improving the conditions under which the brain can re-evaluate sensory input and reduce the “threat weighting” that amplifies pain.

The review’s protocol-level signals also align with what many clinicians observe: alpha-based training may support relaxation and cortical inhibition of irrelevant activity, while SMR-based approaches may improve sensory gating and stability—two ingredients that can matter when pain feels like it hijacks the whole system. At the same time, the variability across studies is an important clinical reality check. Different people may arrive with different pain drivers: sleep disruption, trauma physiology, anxiety, deconditioning, neuroinflammation, or sensitization. A single protocol cannot be expected to fit everyone.

A particularly interesting theme in the review is integration. Neurofeedback appears most sensible when it is not treated as a lone hero but as part of a broader plan: movement-based rehabilitation for function, psychological approaches for pain-related fear and catastrophizing, and physiologic self-regulation strategies that target autonomic arousal. Neurofeedback can potentially strengthen the “top-down” capacity to shift state, while physical therapy and behavioral strategies capitalize on that improved flexibility to rebuild confidence and function.

At the same time, the evidence limitations matter. Narrative reviews can spotlight patterns, but they cannot settle causality. The field needs more sham-controlled trials, clearer reporting of protocols (electrode placements, reward/inhibit bands, thresholding strategies), consistent outcomes, and longer follow-ups. It also needs better predictors of response—because if we can identify who is most likely to benefit, we can reduce frustration and cost while improving results.

An interpretive thread running under all of this is learning: neurofeedback is essentially practice in state change. Pain often trains the brain toward vigilance; neurofeedback trains the brain toward flexibility. If the nervous system is a car stuck in first gear, neurofeedback is not a new engine—it is driving lessons that help you find second, third, and fourth.

Brendan’s perspective

If there’s one place neurofeedback shines in chronic pain care, it’s in integration. Pain rarely lives in a single lane. It shows up as a sensory signal, yes—but it’s also braided into sleep, stress physiology, attention, mood, and the body’s learned expectations of threat. So a plan that treats pain like a purely “local” problem can end up feeling like turning down the radio while the fire alarm keeps blaring. Neurofeedback can be a powerful way to help the nervous system change state, and it tends to work best when it’s positioned as a training tool inside a broader, practical roadmap.

In clinic, I think about two complementary targets that the review implicitly points toward.

First is the pain signal itself: the brain’s processing of nociception, salience, and sensory gain. Second is the regulation signal: the circuits that let someone downshift arousal, broaden attention, stabilize sleep, and recover after activation. The advantage we have in neurofeedback—especially EEG neurofeedback—is that we can often train either (or both), and we can decide which lever is most efficient and adaptive based on the individual’s context and the nature of their pain. Some people need the nervous system to stop shouting. Others need the nervous system to get better at recovering when it shouts.

Here’s what integration can look like when it’s done with that “two-signal” mindset.

Pair neurofeedback with autonomic regulation work (HRV + breathing). When a person is running chronically sympathetically “tilted,” pain tends to land louder. I often like to anchor the program with heart rate variability (HRV) biofeedback or paced breathing (for example, around 4.5–6 breaths per minute, adjusted for comfort), not as a separate add-on but as a skill that makes neurofeedback learning easier. If someone can reliably shift their physiology toward parasympathetic dominance, their brain becomes a friendlier classroom.

Use neurofeedback to create a stable state platform for rehab and psychotherapy. When pain has been persistent, people often develop pain-related fear, catastrophizing, avoidance, or a sense of helplessness. Neurofeedback can support state stability (sleep, emotional tone, attentional control), which then makes graded exposure to movement, pacing strategies, and cognitive-emotional work more doable. In other words, the goal isn’t simply “less pain,” but “more capacity” so the person can re-enter life—movement, social connection, work—without the nervous system panicking.

Choose the first protocol based on what will move the needle fastest. If sleep is fragile and the system is hypervigilant, stabilizing protocols can be the most adaptive first step. SMR training (typically 12–15 Hz) at central sites (often C3, Cz or C4, depending on the presentation) is a classic way to support sensory gating and sleep stability in many cases. For some clients, alpha up-training (commonly 8–12 Hz) at posterior sites (often POz) can help shift arousal and quiet cortical “noise,” which can indirectly reduce pain amplification.

But if the story is more about the pain signal being sticky—where attention locks onto pain and the brain keeps tagging it as urgent—then protocols that improve flexibility in salience processing may be prioritized. Depending on the person’s patterning, that might involve carefully structured alpha work, targeted inhibits of high-frequency overarousal, or individualized training informed by baseline EEG features.

Sequence matters: regulation first, pain second—or vice versa. One of the most common mistakes I see is treating protocol choice as a philosophical identity (“I’m an alpha person” or “I only do SMR”). Chronic pain care is rarely that tidy. Sometimes the most effective sequence is to train regulation first for a few weeks—sleep, arousal stability, recovery speed—and only then target the pain signal once the system can tolerate more direct modulation. Other times the quickest win is to reduce the sensory gain early, because the person’s distress is so pain-driven that regulation training can’t “land” yet. The review’s heterogeneity actually supports this clinical logic: pain populations are diverse, and a flexible approach is an advantage, not a weakness.

Build a tight feedback loop with functional outcomes. I’m less interested in whether a brainwave moved during a session than whether the person’s life moved between sessions. So I track pain intensity, yes—but also sleep continuity, post-activity recovery time, flare frequency, medication use, movement confidence, and the ability to shift attention away from pain. When a protocol is working, it usually shows up as: fewer spikes, faster recovery, and more “room” in the day for normal life.

Plan for pacing and prevent flares. Pain flares and fatigue spikes are not “failures”; they’re data. If a client flares after training, I treat it like the nervous system telling us we pushed too hard or in the wrong direction. The fix is often simple: reduce session intensity, shorten training blocks, adjust reward/inhibit parameters, and reinforce regulation skills (breathing/HRV) as a buffer. Neurofeedback is learning, and learning goes better when the nervous system feels safe.

The big picture is this: chronic pain pulls people into a narrow physiological and attentional tunnel. A well-integrated biofeedback/neurofeedback plan widens that tunnel. Some days the best strategy is to turn down the pain gain; other days it’s to strengthen the system’s ability to settle, sleep, and recover. The clinical advantage is that we’re not locked into one target—we can train the pain signal and the regulation signal, then adapt the training to what the person’s nervous system is actually ready to learn.

Conclusion

This 2024 narrative review suggests that neurofeedback is a promising, non-invasive addition to chronic pain care, with evidence of pain reduction and improved quality of life across several conditions, including fibromyalgia, headache disorders, chronic low back pain, complex regional pain syndrome, and central neuropathic pain. The review also makes the field’s growing pains clear: protocols differ, outcomes vary, and the overall evidence base still needs stronger sham-controlled trials, clearer protocol reporting, and longer follow-up.

Clinically, the most actionable takeaway is that neurofeedback appears to work best when it is treated as a learning-based tool within a broader plan—one that also supports movement, sleep, mood, and stress physiology. As research moves toward more personalized protocols and more accessible technologies, neurofeedback may become an increasingly practical way to help people retrain the nervous system patterns that keep pain persistent. With careful tailoring, pacing, and integration, it offers a hopeful path toward greater comfort, capability, and confidence.

References

Diotaiuti, P., Corrado, S., Tosti, B., Spica, G., Di Libero, T., D’Oliveira, A., Zanon, A., Rodio, A., Andrade, A., & Mancone, S. (2024). Evaluating the effectiveness of neurofeedback in chronic pain management: A narrative review. Frontiers in Psychology, 15, 1369487. https://doi.org/10.3389/fpsyg.2024.1369487